ISRCTN05534585已完成未知
The use of MElatonin in children with Neuro-developmental Disorders and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study
Alder Hey Children's NHS Foundation Trust (UK)0 个研究点目标入组 114 人开始时间: 2007年1月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current information as of 08/06/2010:
- •1. Children aged 3 years to 15 years 8 months at screening
- •All other inclusion criteria remain the unchanged.
- •Amended as of 29/04/2008:
- •1. Children aged 5 years to 15 years 8 months at screening
- •2. Diagnosis of a neuro-developmental disorder that has been made by a community paediatrician, paediatric neurologist or paediatric neurodisability consultant, categorised as:
- •2.1. Developmental delay alone
- •2.2. Developmental delay and epilepsy*
- •2.3. Developmental delay and autistic spectrum disorder* (ASD)
- •2.4. Developmental delay with ?other? (?other? is defined as the child having a specific genetic/chromosomal disorder), or
- •2.5. Any combination of the above
- •3. Adaptive Behaviour Assessment System (ABAS) questionnaire score with a percentile rank below 7
- •4. Minimum 5 months history of impaired sleep at screening as defined by:
- •4.1. Not falling asleep within one hour of 'lights off' or 'snuggling down to sleep' at age-appropriate times for the child**, and/or:
- •4.2. Less than 6 hours of continuous sleep in three nights out of five
- •5. Children whose parents are likely to be able to use the actigraph and complete sleep diaries
- •6. Children who are able to comply with taking the study drug
- •7. English speaking
- •8. Children whose parents have completed sleep diaries for an average of 5 out of 7 nights at T0W.
- •* In coding the presence of epilepsy and ASD diagnoses, we will require sight of documentation from relevant services that demonstrate appropriate diagnostic assessments and investigations have been used
- •** This will be the child'?s usual bedtime (recorded in the sleep diary) based upon the family?s normal routine
- •Initial information at time of registration:
- •1. Children aged 5 years to 15 years 11 months / < 16 years
- •2. Diagnosis of a neuro-developmental disorder that has been made by a community paediatrician, paediatric neurologist or paediatric neurodisability consultant, categorised as:
- •2.1. developmental delay alone
- •2.2. developmental delay and epilepsy*
- •2.3. developmental delay and Autistic Spectrum Disorder* (ASD)
- •2.4. developmental delay with ?other? (?other? is defined as the child having a specific genetic/chromosomal disorder)
- •3. Vineland assessment score of at least 2 SD below the age standardised reference population mean
- •4. No plans to commence the following medication:
- •4.1. Any benzodiazapines
- •4.2. alimemazine tartrate
- •4.3. amisulpride (Solian)
- •4.4. chlorpromazine (Largactil)
- •4.5. haloperidol (Haldol)
- •4.6. olanzapine (Zyprexa)
- •4.7. risperidone (Risperdal)
- •4.8. sertindole (Serdolect)
- •4.9. sulpiride (Sulpidil, Sulpor)
- •4.10. thioridazine (Melleril)
- •4.11. trifluoperazine (Stelazine)
- •5. Diagnosis of impaired sleep as defined by:
- •5.1. not falling asleep within one hour of 'lights off' or 'snuggling down to sleep' at age-appropriate times for the child**, and/or:
- •5.2. less than 6 hours of continuous sleep in three nights out of five
- •* In coding the presence of epilepsy and ASD diagnoses, we will require sight of documentation from relevant services, that demonstrate appropriate diagnostic assessments and investigations have been used
- •** This will be the child?s usual bedtime based upon the family'?s normal routine
排除标准
- •Current information as of 08/06/2010:
- •2. Children who have been taking the following medication for less than 2 months:
- •2.1. Any benzodiazepines
- •2.2. Amisulpride (Solian)
- •2.3. Chlorpromazine (Largactil)
- •2.4. Haloperidol (Haldol)
- •2.5. Olanzapine (Zyprexa)
- •2.6. Risperidone (Risperdal)
- •2.7. Sertindole (Serdolect)
- •2.8. Sulpiride (Sulpidil, Sulpor)
- •2.9. Thioridazine (Melleril)
- •2.10. Trifluoperazine (Stelazine)
- •4. Current use of sedative or hypnotic drugs, including Choral hydrate, Triclofos, and alimemazine tartrate (Vallergan) (minimum of 14 days washout required)
- •All other exclusion criteria remain unchanged.
- •Amended as of 29/04/2008:
- •1. Children treated with melatonin within 5 months prior to screening
- •2. Any plans to commence the following medication:
- •2.1. Any benzodiazepines
- •2.2. Alimemazine tartrate (Vallergan)
- •2.3. Amisulpride (Solian)
- •2.4. Chlorpromazine (Largactil)
- •2.5. Haloperidol (Haldol)
- •2.6. Olanzapine (Zyprexa)
- •2.7. Risperidone (Risperdal)
- •2.8. Sertindole (Serdolect)
- •2.9. Sulpiride (Sulpidil, Sulpor)
- •2.10. Thioridazine (Melleril)
- •2.11. Trifluoperazine (Stelazine)
- •3. Current use of beta blockers (minimum of 7 days washout required)
- •4. Current use of sedative or hypnotic drugs, including Choral hydrate and Triclofos (minimum of 14 days washout required)
- •5. Children with a known allergy to melatonin
- •6. Regular consumption of alcohol (greater than 3 times per week)
- •7. Children for whom there are suggestive symptoms of Obstructive Sleep Apnoea Syndrome (OSAS) (such as combinations of snoring, gasping, excessive sweating or stopping breathing during sleep), physical signs supportive of OSAS (such as very large tonsils/very small chin), or results of investigations suggesting OSAS (such as overnight pulse oximetry or polysomnography) for which the child should be referred to appropriate respiratory or ENT colleagues for specific assessment and treatment
- •8. Girls or young women who are pregnant at the time of screening (T-4W)
- •9. Currently participating in a conflicting clinical study or participation in a clinical study involving a medicinal product within the last 3 months
- •Previous exclusion criteria:
- •1. Children treated with melatonin within 6 months prior to screening
- •2. Children whose parents are unlikely to be able to use the actiwatch or complete sleep diaries, or both
- •3. Children where there may be a problem with major non-concordance with medication
- •4. Girls or young women who are pregnant at the time of screening (4 weeks prior to randomisation)
- •5. Currently participating in a conflicting clinical study or participation in a clinical study involving a medicinal product within the last 30 days
研究者
相似试验
进行中（未招募）
1 期
MENDS: The use of MElatonin in children with Neuro-developmental Disorders and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study - MENDSEUCTR2006-004025-28-GBRoyal Liverpool Children’s NHS Trust
尚未招募
不适用
EFFECT OF TABLET MELATONIN FOR SLEEP PROBLEMS IN CHILDREN WITH CEREBRAL PALSYCTRI/2020/09/027813GIRE POOJA K
已完成
3 期
Investigating The Effect Of Melatonin On Infantile ColicInfantile colic.Infantile colicR10.4IRCT20080930001285N2Yazd University of Medical Sciences70
已完成
不适用
Melatonin treatment for sleep problems in children with autism: a randomised controlled crossover trialPervasive developmental disordersISRCTN77884120orth Yorkshire and York Primary Care Trust (UK)32
已完成
不适用
MELatonin for children with idiopathic chronic sleep onset insomnia, with or without attention deficit hyperkinesia disorder - a DOSe finding trial: a randomised placebo-controlled double-blind parallel group trialInsomnia, Attention Deficit Hyperactivity Disorder (ADHD), sleep disordersMental and Behavioural DisordersBehavioural DisordersISRCTN20033346Hospital Pharmacy of the Valley of Gelderland (Ziekenhuisapotheek Gelderse Vallei) (The Netherlands)150